Bank of Montreal Launches $1 Million Autocallable Note Offering Linked to Abbott, Regeneron, and Intuitive Surgical

Reference Asset Selection and Initial Pricing Levels

The disclosure specifies three reference assets underlying these notes. Abbott Laboratories shares were valued at an initial level of $103.06 on the pricing date. Regeneron Pharmaceuticals common stock was set at an initial level of $656.01, while Intuitive Surgical shares were assigned an initial level of $337.50. The notes use "the least performing" of these three stocks to determine final payouts, meaning the worst-performing asset controls downside losses at maturity. This structure introduces concentration risk, as investors' returns depend heavily on whichever reference asset declines most significantly over the three-year term.

The initial value of the notes was estimated at $949.46 per $1,000 in principal amount on the pricing date. Bank of Montreal retained proceeds of $992,500 after accounting for an agent's commission of $7,500, representing 0.75% of the $1,000,000 offering. The pricing structure offered to the public was 100% of par value, though certain fee-based advisory accounts received adjusted pricing between $992.50 and $1,000 per $1,000 in principal amount.

Monthly Contingent Coupon Mechanics and Memory Feature

The notes provide for contingent monthly interest payments beginning in August 2026, with observation dates typically falling around the 25th to 27th of each month and corresponding payment dates around the 28th to 31st. The contingent interest rate is 1.1667% per month, equating to approximately 14.00% per annum, payable only if certain conditions are met on each observation date. Each contingent coupon payment, when due, equals $11.667 for every $1,000 in principal amount. The disclosure states that all three reference assets must close at or above their respective coupon barrier levels—60% of initial levels for Abbott ($61.84), Regeneron ($393.61), and Intuitive Surgical ($202.50)—for the coupon to be paid that month.

A distinctive feature of these notes is the memory coupon mechanism. If any reference asset falls below its coupon barrier level on an observation date, the coupon for that month is not paid immediately but instead accrues in memory. On any subsequent observation date where all three reference assets meet their coupon barrier thresholds, all previously unpaid accrued coupons are paid together with the current month's coupon. However, the disclosure makes clear that once a missed coupon has been paid under the memory feature, it is not paid again on any further observation date. If any reference asset remains below its coupon barrier level on every observation date throughout the note's term, investors will receive no contingent coupons whatsoever.

Autocall Feature and Early Redemption Mechanism

Beginning on January 26, 2027, the notes incorporate an autocall feature that may trigger automatic redemption. On any observation date from January 2027 forward, if the closing level of each reference asset exceeds its call level—which is 100% of its respective initial level—the notes are automatically redeemed. On the subsequent contingent coupon payment date designated as the call settlement date, investors receive their original principal amount plus any contingent coupon otherwise due on that date. After redemption occurs, no further payments are made on the notes.

This autocall structure means investors cannot participate in any appreciation of the reference assets beyond the initial level. The disclosure explicitly states that investors must be "willing to have their notes automatically redeemed prior to maturity" and "be willing to forego any potential to participate in the appreciation of the Reference Assets." The earliest possible redemption would occur if all three stocks remain above their initial levels by January 26, 2027. The observation dates for potential automatic redemption continue monthly through June 26, 2029, just before the maturity date.

Principal Protection at Maturity and Trigger Level Mechanics

The notes do not guarantee return of principal at maturity. Instead, repayment depends on whether a trigger event occurs. A trigger event is defined as the final level of any reference asset declining from its initial level to below its trigger level by the valuation date of July 26, 2029. The trigger levels are set at 50% of initial levels: Abbott at $51.53, Regeneron at $328.01, and Intuitive Surgical at $168.75. If no trigger event has occurred—meaning all three reference assets remain at or above 50% of their initial levels by maturity—investors receive their full principal amount plus any final contingent coupon due.

If a trigger event has occurred, investors suffer principal loss equal to 1% of the principal amount for each 1% decline in the least performing reference asset from its initial level to its final level. The disclosure illustrates this with a formulaic structure: "you will receive a cash amount at maturity that is less than the principal amount, together with the final Contingent Coupon, if payable." This means the worst-performing stock could decline 50% before hitting the trigger level, and even within that range, losses accelerate proportionally. An investor could lose the entire principal amount if the least performing asset falls to zero.

Risk Warnings and Credit Exposure

The disclosure contains explicit risk warnings. Investors are told they must "be willing to lose some or all of their principal at maturity" and that "investing in the notes is not equivalent to a direct investment in the Reference Assets." The notes lack any guarantee of return of capital. All payments on the notes are subject to the credit risk of Bank of Montreal, meaning if Bank of Montreal faces financial distress or default, investors may not receive promised payments even if the reference assets perform well. The notes will not be listed on any securities exchange, creating potential liquidity constraints for investors wishing to exit their positions before maturity.

The disclosure specifies that detailed risk considerations appear in supplementary sections including "Selected Risk Considerations" beginning on page P-5 and "Additional Risk Factors Relating to the Notes" beginning on page PS-6 of the product supplement. The disclosure also references a "Risk Factors" section beginning on page S-1 of the prospectus supplement and page 8 of the prospectus. These sections provide expanded discussion of market, counterparty, liquidity, and structural risks not fully summarized in the pricing supplement itself.

Regulatory Status and Non-Convertibility

Bank of Montreal emphasizes that the Securities and Exchange Commission and state securities commissions have not approved or disapproved these notes, nor have they passed upon the accuracy of the pricing supplement, product supplement, prospectus supplement, or prospectus. The disclosure carries a notice that any representation to the contrary constitutes a criminal offense. The notes are characterized as unsecured obligations of Bank of Montreal and are explicitly stated not to be savings accounts or deposits insured by the Federal Deposit Insurance Corporation, the Deposit Insurance Fund, the Canada Deposit Insurance Corporation, or any other governmental agency.

An important regulatory feature is disclosed: the notes will not be subject to conversion into Bank of Montreal common shares or the common shares of any affiliate under subsection 39.2(2.3) of the Canada Deposit Insurance Corporation Act. This clarification removes any ambiguity regarding potential forced conversion of the notes into equity in a stress scenario affecting the issuer. The notes will be issued in minimum denominations of $1,000 and integral multiples of $1,000, restricting participation to investors capable of purchasing at least the minimum amount.

Distribution and Agent Commission Structure

Bank of Montreal's subsidiary, BMO Capital Markets Corp., served as the agent for this offering. The agent's commission totaled $7,500, or 0.75% of the principal amount. The disclosure notes that "the total 'Agent's Commission' and 'Proceeds to Bank of Montreal' specified above reflect the aggregate amounts at the time Bank of Montreal established its hedge positions on or prior to the Pricing Date, which may have been variable and fluctuated depending on market conditions at such times." This language indicates that Bank of Montreal's net proceeds and the agent commission may have varied based on the cost and market conditions of hedging activities.

The disclosure also reveals that certain dealers who purchased the notes for sale to fee-based advisory accounts may have foregone some or all of their selling concessions, fees, or commissions. In such cases, the public offering price for investors in those fee-based advisory accounts was between $992.50 and $1,000 per $1,000 in principal amount, creating a pricing variation depending on distribution channel. This arrangement suggests that the notes were distributed through multiple channels with different economic terms for different investor types.

Valuation Timeline and Settlement Details

The disclosure establishes a specific timeline for the notes' lifecycle. The pricing date was July 24, 2026, with settlement occurring on July 29, 2026. Monthly observation dates begin with August 26, 2026, and continue on approximately the 25th to 27th of each month through June 26, 2029. The valuation date—the date on which the final levels of all reference assets are determined—is July 26, 2029, just five days before the maturity date of July 31, 2029. This tight timeline between valuation and maturity means investors have minimal time between learning their final payoff and receiving it.

The contingent coupon payment schedule runs from August 31, 2026, through June 29, 2029, with the final coupon potentially payable on the maturity date of July 31, 2029. The observation and payment dates are staggered by several days, typically providing three to six business days between the observation date and the payment date for Bank of Montreal to process the note terms and execute payments. This schedule ensures that the notes' three-year term captures approximately 36 monthly observation cycles, creating frequent opportunities for coupon accrual, memory mechanism activation, or autocall triggering.

Estimated Value and Market Pricing Considerations

Bank of Montreal estimated the initial value of the notes at $949.46 per $1,000 in principal amount as of the pricing date. This valuation represented a discount to the 100% public offering price, reflecting the economic value assigned to the issuer's embedded options and the notes' derivative structure. The disclosure explicitly states that "the actual value of the notes at any time will reflect many factors and cannot be predicted with accuracy," cautioning investors against relying on the initial valuation estimate for decision-making.

The gap between the $949.46 estimated initial value and the $1,000 public offering price suggests that the spread compensates Bank of Montreal for issuing the notes and funding the embedded autocall and barrier features. This valuation methodology is standard for structured products but highlights the cost of the embedded derivatives to investors. The notes' value will fluctuate based on changes in the prices of Abbott, Regeneron, and Intuitive Surgical shares, interest rate volatility, time decay, and credit spreads on Bank of Montreal obligations, among other factors.